22:21 , Jul 11, 2019 |  BC Innovations  |  Translation in Brief

Fc sugar additions control fetal transfer of maternal antibodies

Two groups have identified determinants of antibody transfer across the placenta, paving a way to maternal delivery of therapies that boost neonatal protection against infections. The teams homed in on IgG Fc sugar additions as...
14:15 , Mar 20, 2019 |  BC Extra  |  Company News

Alexion augmenting pipeline with Zealand, Affibody deals

Alexion took a pair of steps toward further rebuilding its pipeline Wednesday, gaining rights to targets in the complement pathway via a deal with Zealand and adding a clinical-stage molecule from Affibody for IgG-mediated autoimmune...
01:56 , Mar 8, 2019 |  BC Innovations  |  Targets & Mechanisms

Oral insulin innovation

While clinical data suggest an oral insulin product may finally be within reach, the technology struggles to compete with injectables on price and efficacy. A handful of academics and companies are pushing preclinical innovation in...
01:47 , Feb 8, 2019 |  BC Week In Review  |  Company News

Halozyme grants argenx access to Enhanze subcutaneous delivery tech

Halozyme Therapeutics Inc. (NASDAQ:HALO) granted argenx S.E. (NASDAQ:ARGX) exclusive rights to use Halozyme's Enhanze subcutaneous drug delivery technology in combination with any product targeting the human neonatal Fc receptor FcRn, including argenx lead compound efgartigimod...
19:35 , Jan 24, 2019 |  BC Innovations  |  Emerging Company Profile

Cabaletta’s CAAR Ts for autoimmunity

Cabaletta Bio Inc.’s CAAR T therapy is geared to treat B cell-mediated autoimmunity without wiping out all B cells. The company is betting an antigen-specific approach will yield efficacy without CARs’ safety drawbacks. Cabaletta spun...
18:08 , Dec 7, 2018 |  BC Week In Review  |  Company News

argenx gets $500M up front from Janssen for CD70 mAb

argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) will receive $500 million up front from Janssen Pharmaceuticals Inc. in exchange for exclusive, worldwide rights to anti-CD70 mAb cusatuzumab (ARGX-110). The upfront payment comprises $300 million in cash from the...
00:27 , Dec 4, 2018 |  BC Extra  |  Company News

argenx gets $500M up front from Janssen for CD70 mAb

argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) will receive $500 million up front from Janssen Pharmaceuticals Inc. in exchange for exclusive, worldwide rights to anti-CD70 mAb cusatuzumab (ARGX-110). The upfront payment comprises $300 million in cash from the...
00:48 , Oct 6, 2018 |  BioCentury  |  Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
20:41 , Oct 5, 2018 |  BC Week In Review  |  Company News

Momenta cutting biosimilar programs, headcount

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) said it plans to terminate five biosimilar development programs under its 2016 co-development deal with Mylan N.V. (NASDAQ:MYL) and reduce headcount by about 50% to focus on its novel pipeline. The...
23:52 , Oct 1, 2018 |  BC Extra  |  Company News

Momenta cutting biosimilar programs, headcount

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) said it plans to terminate five biosimilar development programs under its 2016 co-development deal with Mylan N.V. (NASDAQ:MYL) and reduce headcount by about 50% to focus on its novel pipeline. The...